C. Lowry Barnes
Concepts (606)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 57 | 2024 | 289 | 12.660 |
Why?
| | Arthroplasty, Replacement, Hip | 52 | 2024 | 266 | 12.580 |
Why?
| | Antibodies, Neutralizing | 22 | 2025 | 79 | 4.450 |
Why?
| | Allergens | 8 | 2025 | 141 | 3.030 |
Why?
| | Antibodies, Viral | 14 | 2025 | 110 | 2.470 |
Why?
| | Orthopedics | 10 | 2022 | 53 | 2.430 |
Why?
| | Osteoarthritis, Knee | 11 | 2022 | 97 | 2.250 |
Why?
| | Humans | 165 | 2025 | 52332 | 2.100 |
Why?
| | Health Literacy | 5 | 2019 | 132 | 2.020 |
Why?
| | Length of Stay | 18 | 2024 | 659 | 1.980 |
Why?
| | Coronavirus Infections | 9 | 2021 | 188 | 1.870 |
Why?
| | Pneumonia, Viral | 8 | 2020 | 177 | 1.870 |
Why?
| | Fungi | 5 | 2025 | 51 | 1.840 |
Why?
| | Air Pollution, Indoor | 5 | 2025 | 27 | 1.800 |
Why?
| | Reoperation | 13 | 2024 | 465 | 1.790 |
Why?
| | Knee Joint | 19 | 2023 | 165 | 1.780 |
Why?
| | Patient Readmission | 13 | 2024 | 243 | 1.780 |
Why?
| | Aged | 54 | 2024 | 10108 | 1.680 |
Why?
| | Arthroplasty, Replacement | 5 | 2019 | 27 | 1.680 |
Why?
| | Hip Prosthesis | 6 | 2021 | 71 | 1.670 |
Why?
| | Medicare | 17 | 2024 | 274 | 1.660 |
Why?
| | Analgesics, Opioid | 10 | 2024 | 590 | 1.660 |
Why?
| | Preoperative Care | 5 | 2018 | 172 | 1.590 |
Why?
| | Epitopes | 12 | 2025 | 65 | 1.490 |
Why?
| | Retrospective Studies | 43 | 2024 | 6576 | 1.480 |
Why?
| | Hypersensitivity | 6 | 2018 | 81 | 1.400 |
Why?
| | United States | 30 | 2024 | 5183 | 1.380 |
Why?
| | Pandemics | 12 | 2022 | 585 | 1.360 |
Why?
| | Periprosthetic Fractures | 4 | 2022 | 11 | 1.300 |
Why?
| | Postoperative Complications | 13 | 2024 | 1066 | 1.240 |
Why?
| | Pain, Postoperative | 7 | 2024 | 169 | 1.230 |
Why?
| | Range of Motion, Articular | 8 | 2022 | 108 | 1.200 |
Why?
| | Prosthesis-Related Infections | 6 | 2023 | 107 | 1.200 |
Why?
| | Joint Diseases | 3 | 2018 | 39 | 1.180 |
Why?
| | HIV Antibodies | 6 | 2022 | 15 | 1.180 |
Why?
| | HIV-1 | 8 | 2022 | 59 | 1.170 |
Why?
| | Critical Pathways | 3 | 2017 | 35 | 1.150 |
Why?
| | Golf | 3 | 2023 | 9 | 1.150 |
Why?
| | Patient Discharge | 14 | 2022 | 317 | 1.150 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 5 | 2022 | 5 | 1.150 |
Why?
| | Hip Dislocation | 2 | 2019 | 17 | 1.110 |
Why?
| | Orthopedic Procedures | 6 | 2020 | 71 | 1.100 |
Why?
| | Patient Education as Topic | 5 | 2018 | 321 | 1.070 |
Why?
| | Comprehension | 2 | 2018 | 113 | 1.050 |
Why?
| | Middle Aged | 40 | 2024 | 13011 | 1.000 |
Why?
| | Respiratory Tract Diseases | 2 | 2018 | 28 | 0.990 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 94 | 0.980 |
Why?
| | Male | 56 | 2024 | 26696 | 0.950 |
Why?
| | HIV Envelope Protein gp120 | 4 | 2020 | 13 | 0.950 |
Why?
| | Prosthesis Failure | 5 | 2020 | 111 | 0.940 |
Why?
| | Climate Change | 2 | 2018 | 53 | 0.940 |
Why?
| | Respiratory Hypersensitivity | 1 | 2025 | 17 | 0.940 |
Why?
| | Immunoglobulin G | 5 | 2021 | 195 | 0.930 |
Why?
| | Antigens, Fungal | 1 | 2025 | 20 | 0.930 |
Why?
| | Female | 55 | 2025 | 28103 | 0.910 |
Why?
| | Osteoarthritis | 6 | 2023 | 61 | 0.890 |
Why?
| | Risk Factors | 18 | 2023 | 3872 | 0.890 |
Why?
| | Joint Instability | 2 | 2022 | 43 | 0.890 |
Why?
| | Pain Management | 3 | 2016 | 178 | 0.890 |
Why?
| | Pollen | 3 | 2018 | 4 | 0.850 |
Why?
| | Hip | 2 | 2020 | 23 | 0.810 |
Why?
| | Anthozoa | 1 | 2022 | 5 | 0.800 |
Why?
| | Cryoelectron Microscopy | 8 | 2025 | 13 | 0.800 |
Why?
| | Diterpenes | 1 | 2022 | 31 | 0.790 |
Why?
| | Polysaccharides | 6 | 2022 | 56 | 0.780 |
Why?
| | Lordosis | 1 | 2022 | 4 | 0.780 |
Why?
| | Prosthesis Design | 4 | 2021 | 255 | 0.770 |
Why?
| | Opioid-Related Disorders | 5 | 2023 | 400 | 0.770 |
Why?
| | Kyphosis | 1 | 2022 | 16 | 0.770 |
Why?
| | Hospitals | 10 | 2024 | 181 | 0.760 |
Why?
| | Knee | 3 | 2021 | 25 | 0.750 |
Why?
| | HIV Infections | 6 | 2022 | 388 | 0.750 |
Why?
| | Housing | 4 | 2016 | 49 | 0.750 |
Why?
| | Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.710 |
Why?
| | Blood Transfusion | 3 | 2016 | 128 | 0.710 |
Why?
| | Animals | 27 | 2025 | 13524 | 0.710 |
Why?
| | Prostatic Hyperplasia | 1 | 2021 | 37 | 0.700 |
Why?
| | Dust | 3 | 2019 | 23 | 0.690 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 291 | 0.690 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2020 | 16 | 0.680 |
Why?
| | Knee Prosthesis | 4 | 2023 | 52 | 0.680 |
Why?
| | Antibodies, Monoclonal | 12 | 2025 | 481 | 0.640 |
Why?
| | Disease Susceptibility | 1 | 2019 | 96 | 0.630 |
Why?
| | Asthma | 4 | 2017 | 316 | 0.630 |
Why?
| | Aged, 80 and over | 13 | 2024 | 3391 | 0.630 |
Why?
| | Environment | 1 | 2019 | 88 | 0.620 |
Why?
| | Anesthesia, General | 4 | 2024 | 98 | 0.620 |
Why?
| | Surgery Department, Hospital | 1 | 2019 | 4 | 0.620 |
Why?
| | Bone Cements | 1 | 2019 | 30 | 0.610 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 26 | 0.610 |
Why?
| | Societies, Medical | 2 | 2020 | 200 | 0.600 |
Why?
| | Hip Joint | 2 | 2020 | 56 | 0.600 |
Why?
| | Diabetic Foot | 1 | 2019 | 76 | 0.590 |
Why?
| | Food Hypersensitivity | 1 | 2019 | 100 | 0.590 |
Why?
| | Cost Savings | 2 | 2017 | 58 | 0.590 |
Why?
| | Models, Molecular | 9 | 2021 | 352 | 0.580 |
Why?
| | Comorbidity | 5 | 2018 | 624 | 0.580 |
Why?
| | Arthroplasty | 4 | 2023 | 28 | 0.570 |
Why?
| | Yoga | 1 | 2018 | 14 | 0.570 |
Why?
| | Hospitals, Teaching | 2 | 2019 | 53 | 0.550 |
Why?
| | Environmental Exposure | 5 | 2025 | 216 | 0.550 |
Why?
| | Protein Binding | 9 | 2024 | 680 | 0.540 |
Why?
| | Inpatients | 7 | 2020 | 205 | 0.540 |
Why?
| | Clinical Protocols | 1 | 2017 | 108 | 0.540 |
Why?
| | Postoperative Period | 6 | 2018 | 170 | 0.530 |
Why?
| | Quadriceps Muscle | 4 | 2022 | 47 | 0.520 |
Why?
| | Arthritis, Infectious | 3 | 2023 | 43 | 0.520 |
Why?
| | AIDS Vaccines | 3 | 2021 | 11 | 0.520 |
Why?
| | Patient Navigation | 1 | 2016 | 13 | 0.520 |
Why?
| | B-Lymphocytes | 7 | 2024 | 185 | 0.520 |
Why?
| | Antifibrinolytic Agents | 1 | 2016 | 17 | 0.510 |
Why?
| | Binding Sites | 6 | 2024 | 379 | 0.510 |
Why?
| | Tranexamic Acid | 1 | 2016 | 16 | 0.510 |
Why?
| | Early Ambulation | 1 | 2016 | 5 | 0.500 |
Why?
| | Anti-Bacterial Agents | 4 | 2023 | 801 | 0.500 |
Why?
| | Musculoskeletal Pain | 1 | 2016 | 7 | 0.500 |
Why?
| | Caregivers | 1 | 2018 | 238 | 0.490 |
Why?
| | Publishing | 1 | 2016 | 37 | 0.480 |
Why?
| | Immunity, Innate | 1 | 2016 | 117 | 0.480 |
Why?
| | Quality of Health Care | 1 | 2017 | 187 | 0.480 |
Why?
| | Periodicals as Topic | 1 | 2016 | 61 | 0.460 |
Why?
| | Analgesia, Epidural | 1 | 2015 | 28 | 0.460 |
Why?
| | Bupivacaine | 1 | 2015 | 30 | 0.450 |
Why?
| | Narcotics | 3 | 2020 | 108 | 0.440 |
Why?
| | Adult | 24 | 2024 | 14137 | 0.440 |
Why?
| | Intermittent Pneumatic Compression Devices | 1 | 2014 | 2 | 0.440 |
Why?
| | Air Pollutants | 2 | 2013 | 75 | 0.430 |
Why?
| | Epilepsy | 1 | 2016 | 186 | 0.430 |
Why?
| | Treatment Outcome | 10 | 2024 | 5407 | 0.420 |
Why?
| | Exercise | 1 | 2018 | 548 | 0.420 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 75 | 0.400 |
Why?
| | Cross Reactions | 3 | 2021 | 41 | 0.400 |
Why?
| | DNA Methylation | 1 | 2016 | 592 | 0.390 |
Why?
| | Health Expenditures | 3 | 2017 | 73 | 0.380 |
Why?
| | Activities of Daily Living | 3 | 2023 | 182 | 0.380 |
Why?
| | Mutation | 7 | 2021 | 1351 | 0.380 |
Why?
| | Work Schedule Tolerance | 2 | 2021 | 5 | 0.370 |
Why?
| | Sleep Disorders, Circadian Rhythm | 2 | 2021 | 5 | 0.370 |
Why?
| | Osteonecrosis | 2 | 2022 | 35 | 0.360 |
Why?
| | Mice | 13 | 2025 | 5966 | 0.360 |
Why?
| | Receptors, Virus | 2 | 2021 | 26 | 0.360 |
Why?
| | Lower Extremity | 3 | 2023 | 99 | 0.340 |
Why?
| | Crystallography, X-Ray | 4 | 2021 | 156 | 0.330 |
Why?
| | Pain | 4 | 2024 | 360 | 0.330 |
Why?
| | Odds Ratio | 5 | 2019 | 558 | 0.330 |
Why?
| | Cross-Sectional Studies | 6 | 2018 | 1676 | 0.320 |
Why?
| | Acetabulum | 3 | 2020 | 38 | 0.320 |
Why?
| | Neutralization Tests | 7 | 2023 | 27 | 0.320 |
Why?
| | Young Adult | 10 | 2021 | 4318 | 0.320 |
Why?
| | Tibial Fractures | 2 | 2021 | 33 | 0.310 |
Why?
| | Cost-Benefit Analysis | 3 | 2021 | 269 | 0.310 |
Why?
| | Osteoarthritis, Hip | 3 | 2019 | 28 | 0.300 |
Why?
| | Fee-for-Service Plans | 2 | 2020 | 18 | 0.300 |
Why?
| | Nanoparticles | 3 | 2021 | 127 | 0.290 |
Why?
| | Movement | 4 | 2021 | 82 | 0.280 |
Why?
| | Crystallization | 3 | 2016 | 33 | 0.280 |
Why?
| | Patient Satisfaction | 2 | 2020 | 284 | 0.280 |
Why?
| | Viscosupplements | 2 | 2017 | 14 | 0.270 |
Why?
| | Hyaluronic Acid | 2 | 2017 | 38 | 0.270 |
Why?
| | Antibody Affinity | 3 | 2021 | 9 | 0.260 |
Why?
| | Mice, Inbred BALB C | 2 | 2025 | 312 | 0.260 |
Why?
| | Adolescent | 10 | 2021 | 6692 | 0.260 |
Why?
| | Recombinant Proteins | 2 | 2020 | 491 | 0.250 |
Why?
| | Indians, North American | 2 | 2018 | 36 | 0.250 |
Why?
| | Risk | 2 | 2017 | 313 | 0.250 |
Why?
| | HEK293 Cells | 4 | 2020 | 232 | 0.240 |
Why?
| | Smoking | 3 | 2018 | 518 | 0.240 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2016 | 70 | 0.240 |
Why?
| | Spores, Fungal | 1 | 2025 | 21 | 0.230 |
Why?
| | Logistic Models | 3 | 2016 | 920 | 0.230 |
Why?
| | Muscle Strength | 3 | 2022 | 131 | 0.230 |
Why?
| | Symbiosis | 1 | 2024 | 12 | 0.230 |
Why?
| | Staphylococcus epidermidis | 1 | 2024 | 18 | 0.230 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 30 | 0.230 |
Why?
| | Reproducibility of Results | 4 | 2022 | 1214 | 0.230 |
Why?
| | RNA Polymerase II | 1 | 2024 | 14 | 0.230 |
Why?
| | Magnesium | 1 | 2024 | 31 | 0.220 |
Why?
| | Catalytic Domain | 1 | 2024 | 61 | 0.220 |
Why?
| | Hip Fractures | 2 | 2023 | 47 | 0.220 |
Why?
| | Molecular Dynamics Simulation | 1 | 2024 | 44 | 0.220 |
Why?
| | Poverty | 2 | 2016 | 219 | 0.220 |
Why?
| | Arthralgia | 3 | 2022 | 44 | 0.220 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 73 | 0.220 |
Why?
| | Cricetulus | 3 | 2020 | 104 | 0.220 |
Why?
| | CHO Cells | 3 | 2020 | 125 | 0.220 |
Why?
| | Delivery of Health Care | 2 | 2017 | 323 | 0.220 |
Why?
| | Protein Multimerization | 3 | 2021 | 57 | 0.220 |
Why?
| | Public Opinion | 2 | 2021 | 21 | 0.210 |
Why?
| | Hospital Mortality | 2 | 2016 | 428 | 0.210 |
Why?
| | Meteorological Concepts | 1 | 2003 | 2 | 0.210 |
Why?
| | Spores | 1 | 2003 | 2 | 0.210 |
Why?
| | Information Services | 1 | 2003 | 13 | 0.210 |
Why?
| | Femur | 2 | 2021 | 133 | 0.210 |
Why?
| | Antibiotic Prophylaxis | 1 | 2023 | 61 | 0.210 |
Why?
| | Knee Injuries | 1 | 2023 | 28 | 0.200 |
Why?
| | Host-Pathogen Interactions | 2 | 2021 | 144 | 0.200 |
Why?
| | Transcription, Genetic | 1 | 2024 | 385 | 0.200 |
Why?
| | Caribbean Region | 1 | 2022 | 5 | 0.200 |
Why?
| | Femoral Fractures | 1 | 2023 | 41 | 0.200 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 42 | 0.200 |
Why?
| | Macaca mulatta | 2 | 2020 | 92 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2024 | 184 | 0.200 |
Why?
| | Braces | 1 | 2002 | 9 | 0.200 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 78 | 0.190 |
Why?
| | Proteins | 2 | 2016 | 354 | 0.190 |
Why?
| | Gait | 2 | 2021 | 88 | 0.190 |
Why?
| | Myositis | 1 | 2022 | 20 | 0.190 |
Why?
| | Outpatients | 2 | 2020 | 125 | 0.190 |
Why?
| | Pain Measurement | 3 | 2019 | 257 | 0.190 |
Why?
| | Pelvis | 1 | 2022 | 67 | 0.190 |
Why?
| | Molecular Structure | 1 | 2022 | 315 | 0.190 |
Why?
| | Critical Illness | 2 | 2021 | 292 | 0.190 |
Why?
| | Sepsis | 2 | 2021 | 229 | 0.190 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 21 | 0.190 |
Why?
| | Osteocytes | 1 | 2024 | 226 | 0.190 |
Why?
| | Injections, Intra-Articular | 3 | 2017 | 38 | 0.180 |
Why?
| | Cricetinae | 2 | 2020 | 194 | 0.180 |
Why?
| | Skin | 1 | 2024 | 418 | 0.180 |
Why?
| | Databases, Factual | 4 | 2019 | 706 | 0.180 |
Why?
| | Metal-on-Metal Joint Prostheses | 1 | 2021 | 5 | 0.180 |
Why?
| | Cost of Illness | 1 | 2022 | 120 | 0.180 |
Why?
| | Glycosylation | 2 | 2019 | 106 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2022 | 101 | 0.180 |
Why?
| | Lumbar Vertebrae | 1 | 2022 | 103 | 0.180 |
Why?
| | Protein Engineering | 2 | 2020 | 18 | 0.180 |
Why?
| | Radiography | 5 | 2019 | 470 | 0.180 |
Why?
| | Vaccines, Synthetic | 1 | 2021 | 21 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2016 | 3049 | 0.180 |
Why?
| | Crowdsourcing | 1 | 2021 | 9 | 0.180 |
Why?
| | Immunity, Humoral | 1 | 2021 | 23 | 0.170 |
Why?
| | Molecular Biology | 1 | 2021 | 27 | 0.170 |
Why?
| | Posture | 1 | 2021 | 66 | 0.170 |
Why?
| | Joints | 2 | 2018 | 19 | 0.170 |
Why?
| | Femur Head Necrosis | 1 | 2020 | 17 | 0.170 |
Why?
| | Vaccination | 2 | 2022 | 297 | 0.170 |
Why?
| | Protein Conformation | 4 | 2024 | 179 | 0.170 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 118 | 0.170 |
Why?
| | Epitope Mapping | 1 | 2020 | 7 | 0.170 |
Why?
| | Dissociative Disorders | 1 | 2020 | 8 | 0.170 |
Why?
| | Hydrocortisone | 1 | 2021 | 111 | 0.170 |
Why?
| | Decompression, Surgical | 1 | 2020 | 50 | 0.170 |
Why?
| | Immunization, Passive | 1 | 2020 | 29 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 114 | 0.170 |
Why?
| | Polyethylene | 1 | 2020 | 18 | 0.170 |
Why?
| | Politics | 1 | 2020 | 28 | 0.170 |
Why?
| | Bariatric Surgery | 1 | 2021 | 44 | 0.170 |
Why?
| | Diagnosis-Related Groups | 2 | 2017 | 18 | 0.170 |
Why?
| | Obesity, Morbid | 1 | 2021 | 88 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2020 | 203 | 0.160 |
Why?
| | Leadership | 1 | 2020 | 104 | 0.160 |
Why?
| | Foot Orthoses | 1 | 2019 | 7 | 0.160 |
Why?
| | External Fixators | 1 | 2019 | 10 | 0.160 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2021 | 136 | 0.160 |
Why?
| | Costs and Cost Analysis | 2 | 2017 | 95 | 0.160 |
Why?
| | Viral Proteins | 1 | 2021 | 164 | 0.160 |
Why?
| | Clone Cells | 1 | 2019 | 77 | 0.160 |
Why?
| | Fracture Healing | 2 | 1996 | 27 | 0.160 |
Why?
| | Tobramycin | 1 | 2019 | 16 | 0.160 |
Why?
| | Antiviral Agents | 1 | 2020 | 177 | 0.150 |
Why?
| | After-Hours Care | 1 | 2019 | 12 | 0.150 |
Why?
| | Models, Neurological | 1 | 2019 | 52 | 0.150 |
Why?
| | Systems Biology | 1 | 2019 | 33 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 106 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2019 | 55 | 0.150 |
Why?
| | HIV Envelope Protein gp41 | 1 | 2018 | 5 | 0.150 |
Why?
| | Maternal Exposure | 1 | 2019 | 101 | 0.150 |
Why?
| | Bayes Theorem | 1 | 2019 | 120 | 0.150 |
Why?
| | Hospitals, University | 1 | 2019 | 75 | 0.150 |
Why?
| | Postural Balance | 2 | 2021 | 59 | 0.150 |
Why?
| | Gardening | 1 | 2018 | 2 | 0.150 |
Why?
| | Virus Internalization | 1 | 2018 | 20 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 52 | 0.150 |
Why?
| | Vancomycin | 1 | 2019 | 85 | 0.150 |
Why?
| | Rural Population | 1 | 2023 | 572 | 0.150 |
Why?
| | Plants | 1 | 2018 | 30 | 0.150 |
Why?
| | Immunoglobulin A | 3 | 2024 | 45 | 0.150 |
Why?
| | Exercise Test | 1 | 2019 | 141 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 299 | 0.150 |
Why?
| | Sulfhydryl Compounds | 1 | 2018 | 17 | 0.150 |
Why?
| | Radioisotopes | 1 | 2018 | 17 | 0.150 |
Why?
| | Multiple Sclerosis | 1 | 2019 | 72 | 0.140 |
Why?
| | Medicaid | 2 | 2022 | 264 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 102 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 21 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 44 | 0.140 |
Why?
| | Arsenic | 1 | 2018 | 22 | 0.140 |
Why?
| | Infant, Premature | 1 | 2021 | 319 | 0.140 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 286 | 0.140 |
Why?
| | Smoke-Free Policy | 1 | 2018 | 15 | 0.140 |
Why?
| | Cell Line | 1 | 2020 | 1045 | 0.140 |
Why?
| | Benzodiazepines | 1 | 2018 | 71 | 0.140 |
Why?
| | Tramadol | 1 | 2018 | 30 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2018 | 110 | 0.140 |
Why?
| | Breast Feeding | 1 | 2019 | 197 | 0.140 |
Why?
| | Child, Preschool | 6 | 2016 | 4031 | 0.140 |
Why?
| | Body Mass Index | 2 | 2018 | 689 | 0.140 |
Why?
| | Incidence | 3 | 2019 | 1060 | 0.140 |
Why?
| | Subacute Care | 1 | 2017 | 5 | 0.140 |
Why?
| | Child | 8 | 2020 | 7158 | 0.140 |
Why?
| | Recovery of Function | 1 | 2018 | 200 | 0.140 |
Why?
| | Risk Assessment | 2 | 2019 | 1323 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2018 | 149 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2017 | 14 | 0.130 |
Why?
| | Neurotransmitter Agents | 1 | 2017 | 34 | 0.130 |
Why?
| | Optical Imaging | 1 | 2017 | 25 | 0.130 |
Why?
| | Kansas | 1 | 2016 | 8 | 0.130 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 29 | 0.130 |
Why?
| | Language | 1 | 2018 | 138 | 0.130 |
Why?
| | Reimbursement Mechanisms | 1 | 2017 | 24 | 0.130 |
Why?
| | Immunologic Memory | 3 | 2021 | 32 | 0.130 |
Why?
| | Patient Safety | 1 | 2017 | 104 | 0.130 |
Why?
| | Dietary Proteins | 1 | 2019 | 252 | 0.130 |
Why?
| | Nut Hypersensitivity | 1 | 2016 | 3 | 0.130 |
Why?
| | Cocos | 1 | 2016 | 2 | 0.130 |
Why?
| | Fractures, Open | 1 | 1996 | 8 | 0.130 |
Why?
| | Fractures, Bone | 4 | 1992 | 107 | 0.130 |
Why?
| | Fluorescent Dyes | 1 | 2017 | 91 | 0.130 |
Why?
| | Football | 1 | 2018 | 75 | 0.130 |
Why?
| | Nuts | 1 | 2016 | 8 | 0.130 |
Why?
| | Time Factors | 5 | 2021 | 2958 | 0.130 |
Why?
| | Zinc | 1 | 2017 | 56 | 0.130 |
Why?
| | Hospitals, Community | 1 | 2016 | 19 | 0.130 |
Why?
| | Glutamic Acid | 1 | 2017 | 105 | 0.130 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 236 | 0.130 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 139 | 0.130 |
Why?
| | Social Class | 1 | 2016 | 93 | 0.130 |
Why?
| | Social Support | 1 | 2018 | 268 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 303 | 0.120 |
Why?
| | Quality Improvement | 1 | 2018 | 222 | 0.120 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 17 | 0.120 |
Why?
| | Peer Review, Research | 1 | 2016 | 13 | 0.120 |
Why?
| | Anesthesia, Conduction | 1 | 2016 | 15 | 0.120 |
Why?
| | Anemia | 1 | 2016 | 74 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2016 | 48 | 0.120 |
Why?
| | Hyperalgesia | 1 | 2016 | 41 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 58 | 0.120 |
Why?
| | Breast Neoplasms | 1 | 2024 | 1206 | 0.120 |
Why?
| | Hemoglobins | 1 | 2016 | 110 | 0.120 |
Why?
| | Prescription Drug Misuse | 1 | 2016 | 33 | 0.120 |
Why?
| | Chronic Disease | 1 | 2018 | 583 | 0.120 |
Why?
| | Ambulatory Care Facilities | 1 | 2016 | 124 | 0.120 |
Why?
| | Pneumonia | 1 | 2016 | 125 | 0.120 |
Why?
| | Environmental Health | 1 | 2015 | 14 | 0.120 |
Why?
| | Injections, Epidural | 1 | 2015 | 11 | 0.120 |
Why?
| | Liposomes | 1 | 2015 | 53 | 0.110 |
Why?
| | Arthroplasty, Replacement, Ankle | 1 | 2014 | 3 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2016 | 590 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 122 | 0.110 |
Why?
| | Cohort Studies | 4 | 2021 | 1532 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2269 | 0.110 |
Why?
| | Age Factors | 1 | 2017 | 1127 | 0.110 |
Why?
| | Anesthetics, Local | 1 | 2015 | 79 | 0.110 |
Why?
| | Phylogeny | 3 | 2021 | 234 | 0.110 |
Why?
| | Bacteria | 1 | 2015 | 220 | 0.110 |
Why?
| | Drug Overdose | 1 | 2016 | 163 | 0.110 |
Why?
| | Socioeconomic Factors | 3 | 2023 | 606 | 0.110 |
Why?
| | Kinetics | 3 | 2021 | 623 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 315 | 0.100 |
Why?
| | Arthropod Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2016 | 1021 | 0.100 |
Why?
| | Antigens, Dermatophagoides | 1 | 2013 | 4 | 0.100 |
Why?
| | Humeral Fractures | 1 | 1992 | 8 | 0.100 |
Why?
| | Cysteine Endopeptidases | 1 | 2013 | 71 | 0.100 |
Why?
| | Joint Prosthesis | 1 | 1992 | 12 | 0.100 |
Why?
| | Patient Positioning | 1 | 2013 | 31 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2014 | 90 | 0.100 |
Why?
| | Pulmonary Embolism | 1 | 2014 | 84 | 0.100 |
Why?
| | Mass Screening | 1 | 2016 | 357 | 0.100 |
Why?
| | Carpal Bones | 1 | 1992 | 2 | 0.100 |
Why?
| | Synostosis | 1 | 1992 | 2 | 0.100 |
Why?
| | Environmental Monitoring | 1 | 2013 | 74 | 0.100 |
Why?
| | Shoulder Joint | 1 | 1992 | 38 | 0.100 |
Why?
| | Glycoproteins | 1 | 2013 | 123 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 315 | 0.100 |
Why?
| | Diseases in Twins | 1 | 1992 | 14 | 0.100 |
Why?
| | Health Promotion | 1 | 2015 | 268 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2014 | 239 | 0.090 |
Why?
| | Fungal Proteins | 1 | 2013 | 118 | 0.090 |
Why?
| | Tibia | 2 | 2023 | 112 | 0.090 |
Why?
| | Arm Injuries | 1 | 1991 | 10 | 0.090 |
Why?
| | Lidocaine | 1 | 1991 | 46 | 0.090 |
Why?
| | Immune Evasion | 2 | 2021 | 15 | 0.090 |
Why?
| | Aging | 1 | 1996 | 708 | 0.090 |
Why?
| | Immunoglobulin E | 2 | 2016 | 92 | 0.090 |
Why?
| | Epitopes, B-Lymphocyte | 2 | 2021 | 4 | 0.090 |
Why?
| | Stroke | 1 | 2016 | 509 | 0.090 |
Why?
| | Immunization | 2 | 2021 | 68 | 0.090 |
Why?
| | Nerve Block | 1 | 1991 | 43 | 0.090 |
Why?
| | Antigens, Viral | 2 | 2021 | 43 | 0.090 |
Why?
| | Electrons | 2 | 2024 | 21 | 0.090 |
Why?
| | Mental Disorders | 1 | 2016 | 428 | 0.090 |
Why?
| | Lasers | 2 | 2024 | 65 | 0.090 |
Why?
| | Osteoclasts | 2 | 2024 | 428 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1323 | 0.090 |
Why?
| | Fatigue | 2 | 2021 | 125 | 0.090 |
Why?
| | Immunoglobulin M | 2 | 2021 | 60 | 0.090 |
Why?
| | Viral Vaccines | 2 | 2021 | 16 | 0.090 |
Why?
| | Antigen-Antibody Complex | 2 | 2021 | 35 | 0.080 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 2 | 2021 | 6 | 0.080 |
Why?
| | Sleep | 2 | 2021 | 186 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2020 | 36 | 0.080 |
Why?
| | Signal Transduction | 1 | 2017 | 1716 | 0.080 |
Why?
| | Obesity | 1 | 2017 | 1162 | 0.080 |
Why?
| | Molecular Conformation | 2 | 2018 | 69 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2019 | 591 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1110 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 1903 | 0.070 |
Why?
| | Muscle, Skeletal | 2 | 2022 | 809 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 155 | 0.060 |
Why?
| | Quality of Life | 2 | 2022 | 868 | 0.060 |
Why?
| | Inflammation | 2 | 2022 | 642 | 0.060 |
Why?
| | Air | 1 | 2005 | 23 | 0.060 |
Why?
| | Hospitalization | 2 | 2020 | 732 | 0.060 |
Why?
| | Polyethylenes | 2 | 2023 | 14 | 0.060 |
Why?
| | Tetanus Toxin | 1 | 2024 | 1 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 485 | 0.060 |
Why?
| | Antibody Formation | 1 | 2024 | 51 | 0.060 |
Why?
| | Prospective Payment System | 1 | 2024 | 5 | 0.060 |
Why?
| | 5-Methoxytryptamine | 1 | 1994 | 1 | 0.050 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1994 | 7 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 1994 | 23 | 0.050 |
Why?
| | Blastocyst | 1 | 1994 | 15 | 0.050 |
Why?
| | Abnormalities, Drug-Induced | 1 | 1994 | 18 | 0.050 |
Why?
| | Melatonin | 1 | 1994 | 17 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 132 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2024 | 208 | 0.050 |
Why?
| | Fetal Diseases | 1 | 1994 | 62 | 0.050 |
Why?
| | Health Status | 1 | 2005 | 295 | 0.050 |
Why?
| | Quality Indicators, Health Care | 1 | 2024 | 90 | 0.050 |
Why?
| | Particle Size | 1 | 2003 | 78 | 0.050 |
Why?
| | Algorithms | 2 | 2019 | 667 | 0.050 |
Why?
| | Arkansas | 2 | 2019 | 2028 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2023 | 67 | 0.050 |
Why?
| | Aerosols | 1 | 2003 | 75 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 82 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 14 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2023 | 150 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 255 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 70 | 0.050 |
Why?
| | Administration, Oral | 1 | 2023 | 451 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2002 | 80 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2021 | 1 | 0.050 |
Why?
| | Macaca | 1 | 2021 | 9 | 0.050 |
Why?
| | Transcriptome | 1 | 2024 | 367 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 64 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 108 | 0.050 |
Why?
| | New York | 1 | 2021 | 49 | 0.050 |
Why?
| | Chromium | 1 | 2021 | 4 | 0.050 |
Why?
| | Femur Neck | 1 | 2021 | 6 | 0.050 |
Why?
| | Leg | 1 | 2022 | 120 | 0.050 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2021 | 21 | 0.050 |
Why?
| | Cobalt | 1 | 2021 | 17 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2024 | 361 | 0.050 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 15 | 0.050 |
Why?
| | Back | 1 | 2021 | 5 | 0.050 |
Why?
| | Protein Structure, Quaternary | 1 | 2021 | 26 | 0.040 |
Why?
| | Immunoglobulin Variable Region | 1 | 2021 | 17 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 197 | 0.040 |
Why?
| | Torso | 1 | 2021 | 15 | 0.040 |
Why?
| | Fracture Fixation, Internal | 1 | 2021 | 42 | 0.040 |
Why?
| | Immune Sera | 1 | 2021 | 15 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 18 | 0.040 |
Why?
| | APACHE | 1 | 2021 | 25 | 0.040 |
Why?
| | HLA Antigens | 1 | 2021 | 56 | 0.040 |
Why?
| | Indoles | 1 | 1994 | 278 | 0.040 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 7 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 16 | 0.040 |
Why?
| | Directed Molecular Evolution | 1 | 2020 | 2 | 0.040 |
Why?
| | Genome, Viral | 1 | 2021 | 83 | 0.040 |
Why?
| | Intestinal Perforation | 1 | 2021 | 24 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 24 | 0.040 |
Why?
| | Databases, Protein | 1 | 2021 | 28 | 0.040 |
Why?
| | Workplace | 1 | 2021 | 94 | 0.040 |
Why?
| | Government | 1 | 2020 | 3 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 111 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 221 | 0.040 |
Why?
| | Virulence | 1 | 2021 | 167 | 0.040 |
Why?
| | Bone Transplantation | 1 | 2020 | 42 | 0.040 |
Why?
| | Femur Head | 1 | 2020 | 25 | 0.040 |
Why?
| | Psychological Theory | 1 | 2020 | 26 | 0.040 |
Why?
| | Cefazolin | 1 | 2020 | 11 | 0.040 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2021 | 39 | 0.040 |
Why?
| | North America | 1 | 2020 | 73 | 0.040 |
Why?
| | Penicillins | 1 | 2020 | 28 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 99 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1437 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2022 | 283 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2021 | 77 | 0.040 |
Why?
| | Dependovirus | 1 | 2021 | 103 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2021 | 136 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 406 | 0.040 |
Why?
| | Operating Rooms | 1 | 2020 | 27 | 0.040 |
Why?
| | Osteoblasts | 1 | 2023 | 475 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 71 | 0.040 |
Why?
| | Patella | 1 | 2019 | 11 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 46 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 92 | 0.040 |
Why?
| | Intestines | 1 | 2021 | 154 | 0.040 |
Why?
| | Heel | 1 | 2019 | 6 | 0.040 |
Why?
| | Shoes | 1 | 2019 | 14 | 0.040 |
Why?
| | Cross-Priming | 1 | 2019 | 2 | 0.040 |
Why?
| | Sutures | 1 | 2019 | 39 | 0.040 |
Why?
| | Virus Replication | 1 | 2021 | 150 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 2019 | 9 | 0.040 |
Why?
| | Time and Motion Studies | 1 | 2019 | 11 | 0.040 |
Why?
| | Gestational Age | 1 | 2021 | 412 | 0.040 |
Why?
| | Sports Equipment | 1 | 2019 | 4 | 0.040 |
Why?
| | Bone and Bones | 1 | 2023 | 494 | 0.040 |
Why?
| | Software | 1 | 2021 | 279 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2019 | 91 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 211 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2019 | 191 | 0.040 |
Why?
| | Body Weight | 1 | 2021 | 522 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 99 | 0.040 |
Why?
| | Telephone | 1 | 2019 | 71 | 0.040 |
Why?
| | Sequence Analysis, Protein | 1 | 2018 | 19 | 0.040 |
Why?
| | Pollination | 1 | 2018 | 2 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 172 | 0.040 |
Why?
| | Biopsy | 1 | 2021 | 604 | 0.040 |
Why?
| | Sequence Alignment | 1 | 2018 | 125 | 0.040 |
Why?
| | Rabbits | 1 | 2019 | 374 | 0.040 |
Why?
| | Radiochemistry | 1 | 2018 | 2 | 0.040 |
Why?
| | Bombesin | 1 | 2018 | 2 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 149 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2021 | 269 | 0.040 |
Why?
| | Drug Stability | 1 | 2018 | 38 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2019 | 128 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2020 | 292 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2018 | 174 | 0.040 |
Why?
| | Isotope Labeling | 1 | 2018 | 58 | 0.040 |
Why?
| | Prospective Studies | 2 | 2002 | 2428 | 0.030 |
Why?
| | Morphine | 1 | 2018 | 105 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 286 | 0.030 |
Why?
| | Molecular Weight | 1 | 2017 | 82 | 0.030 |
Why?
| | Ultracentrifugation | 1 | 2017 | 10 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2017 | 19 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2017 | 17 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 59 | 0.030 |
Why?
| | Protein Folding | 1 | 2017 | 61 | 0.030 |
Why?
| | Universities | 1 | 2018 | 175 | 0.030 |
Why?
| | Macadamia | 1 | 2016 | 1 | 0.030 |
Why?
| | Solubility | 1 | 2017 | 80 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 126 | 0.030 |
Why?
| | Attitude to Health | 1 | 2018 | 192 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2017 | 112 | 0.030 |
Why?
| | Oxygen | 1 | 2019 | 336 | 0.030 |
Why?
| | Humidity | 1 | 2016 | 4 | 0.030 |
Why?
| | Volatilization | 1 | 2016 | 5 | 0.030 |
Why?
| | Diffusion | 1 | 2016 | 13 | 0.030 |
Why?
| | Probability | 1 | 2016 | 171 | 0.030 |
Why?
| | Protein Array Analysis | 1 | 2015 | 25 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2015 | 52 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1484 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 1201 | 0.030 |
Why?
| | Students | 1 | 2018 | 228 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 115 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2015 | 17 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 1029 | 0.030 |
Why?
| | Temperature | 1 | 2016 | 165 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 521 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 284 | 0.030 |
Why?
| | Corrosion | 1 | 2014 | 4 | 0.030 |
Why?
| | Safety | 1 | 2015 | 79 | 0.030 |
Why?
| | Ions | 1 | 2014 | 32 | 0.030 |
Why?
| | Urban Population | 1 | 2015 | 162 | 0.030 |
Why?
| | Data Collection | 1 | 2016 | 289 | 0.030 |
Why?
| | Sf9 Cells | 1 | 2014 | 2 | 0.030 |
Why?
| | Metals | 1 | 2014 | 35 | 0.030 |
Why?
| | Disease Progression | 1 | 2017 | 870 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2017 | 315 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2021 | 2828 | 0.030 |
Why?
| | Escherichia coli | 1 | 2014 | 187 | 0.030 |
Why?
| | Health Personnel | 1 | 2016 | 252 | 0.030 |
Why?
| | Twins, Monozygotic | 1 | 1992 | 16 | 0.020 |
Why?
| | Thrombophlebitis | 1 | 1992 | 18 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1992 | 116 | 0.020 |
Why?
| | Vena Cava Filters | 1 | 1992 | 30 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1991 | 135 | 0.020 |
Why?
| | Prognosis | 1 | 1996 | 2094 | 0.020 |
Why?
| | Pelvic Bones | 1 | 1990 | 13 | 0.020 |
Why?
| | Dextrans | 1 | 1990 | 16 | 0.020 |
Why?
| | Thromboembolism | 1 | 1990 | 50 | 0.020 |
Why?
| | Leg Injuries | 1 | 1989 | 10 | 0.020 |
Why?
| | Irritants | 1 | 2008 | 1 | 0.020 |
Why?
| | Ergosterol | 1 | 2008 | 10 | 0.020 |
Why?
| | Mycotoxins | 1 | 2008 | 11 | 0.020 |
Why?
| | Glucans | 1 | 2008 | 10 | 0.020 |
Why?
| | Surgical Flaps | 1 | 1989 | 110 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1543 | 0.020 |
Why?
| | Fetal Resorption | 1 | 1994 | 2 | 0.010 |
Why?
| | Pineal Gland | 1 | 1994 | 9 | 0.010 |
Why?
| | Fetal Death | 1 | 1994 | 25 | 0.010 |
Why?
| | Organ Culture Techniques | 1 | 1994 | 44 | 0.010 |
Why?
| | Organ Size | 1 | 1994 | 231 | 0.010 |
Why?
| | Fetus | 1 | 1994 | 194 | 0.010 |
Why?
| | Phlebography | 2 | 1992 | 55 | 0.010 |
Why?
| | Pregnancy | 1 | 1994 | 2674 | 0.010 |
Why?
| | Prothrombin Time | 1 | 1992 | 17 | 0.010 |
Why?
| | Drug Monitoring | 1 | 1992 | 83 | 0.010 |
Why?
| | Warfarin | 1 | 1992 | 83 | 0.010 |
Why?
| | Urogenital System | 1 | 1990 | 4 | 0.010 |
Why?
| | Multiple Trauma | 1 | 1990 | 31 | 0.010 |
Why?
| | Femoral Neck Fractures | 1 | 1990 | 7 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1990 | 166 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 636 | 0.010 |
Why?
| | Prevalence | 1 | 1990 | 1007 | 0.000 |
Why?
|
|
Barnes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|